Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
2026 · 2nd Quarter (Apr 1 - June 30)
NOVO NORDISK, INC.
Filed by ARNOLD & PORTER KAYE SCHOLER LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2026
- Income
- $70,000.00
- Expenses
- Not reported
- Registrant
- ARNOLD & PORTER KAYE SCHOLER LLP
- Client
- NOVO NORDISK, INC.
- Filing UUID
- dc3517c4-58c7-43af-8490-5fec0580648e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Issues related to general compounding.
Issues related to general compounding.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.